Beasley C M, Sayler M E, Cunningham G E, Weiss A M, Masica D N
Division of Clinical Neurosciences, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285.
J Affect Disord. 1990 Nov;20(3):193-200. doi: 10.1016/0165-0327(90)90144-w.
Data regarding open-label treatment with fluoxetine following failure to respond to tricyclic antidepressants (TCAs) or intolerance of TCA side effects, suggest a response rate between 51.4% and 62.1%, depending on the definition of TCA refractoriness employed. Double-blind study of this issue would extend these findings. Fluoxetine is well tolerated in patients unable to tolerate TCAs. Within this population, more than 80% of patients unable to tolerate TCAs found fluoxetine acceptable. Fluoxetine, as an alternative to polypharmaceutical augmentation, may represent a logical choice as the next step in therapy for a patient who has initially been treated with a TCA and has proven refractory or intolerant.
关于在对三环类抗抑郁药（TCA）治疗无反应或对TCA副作用不耐受后使用氟西汀进行开放标签治疗的数据表明，根据所采用的TCA难治性定义，有效率在51.4%至62.1%之间。对此问题的双盲研究将扩展这些发现。氟西汀在无法耐受TCA的患者中耐受性良好。在这一人群中，超过80%无法耐受TCA的患者认为氟西汀是可接受的。作为联合药物增效的替代方法，对于最初接受TCA治疗且已证明难治或不耐受的患者，氟西汀可能是治疗下一步的合理选择。
